MindMed to Present at Leerink’s Global Healthcare Conference 2025
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025. The company's management team will engage in a fireside chat and one-on-one meetings at the event, scheduled for March 11, 2025, at 3:40 PM ET in Miami Beach, FL.
Interested parties can access the presentation through a webcast, with audio recordings and replays remaining available on MindMed's Investor Relations website for up to 90 days after the event.
MindMed (NASDAQ: MNMD), un'azienda biofarmaceutica in fase avanzata focalizzata sui disturbi della salute mentale, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute di Leerink 2025. Il team di gestione dell'azienda parteciperà a una chiacchierata informale e a incontri individuali durante l'evento, programmato per l'11 marzo 2025, alle 15:40 ET a Miami Beach, FL.
Le parti interessate possono accedere alla presentazione tramite un webcast, con registrazioni audio e repliche disponibili sul sito delle Relazioni con gli Investitori di MindMed fino a 90 giorni dopo l'evento.
MindMed (NASDAQ: MNMD), una compañía biofarmacéutica en etapa avanzada enfocada en trastornos de salud cerebral, ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink 2025. El equipo de gestión de la compañía participará en una charla informal y en reuniones uno a uno en el evento, programado para el 11 de marzo de 2025, a las 3:40 PM ET en Miami Beach, FL.
Las partes interesadas pueden acceder a la presentación a través de una transmisión en vivo, con grabaciones de audio y repeticiones disponibles en el sito de Relaciones con Inversores de MindMed durante hasta 90 días después del evento.
MindMed (NASDAQ: MNMD), 뇌 건강 장애에 초점을 맞춘 후기 단계 임상 생명공학 회사가 리어링크 글로벌 헬스케어 컨퍼런스 2025에 참여한다고 발표했습니다. 회사의 경영진은 2025년 3월 11일, 오후 3시 40분 ET에 마이애미 비치, FL에서 열리는 행사에서 파이어사이드 채팅 및 일대일 회의에 참여할 예정입니다.
관심 있는 당사자는 웹캐스트를 통해 발표를 접속할 수 있으며, 행사 후 최대 90일 동안 MindMed의 투자자 관계 웹사이트에서 오디오 녹음 및 재생이 가능합니다.
MindMed (NASDAQ: MNMD), une entreprise biopharmaceutique en phase avancée axée sur les troubles de la santé cérébrale, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink 2025. L'équipe de direction de l'entreprise participera à une discussion informelle et à des réunions individuelles lors de l'événement, prévu pour le 11 mars 2025 à 15h40 ET à Miami Beach, FL.
Les parties intéressées peuvent accéder à la présentation via un webinaire, avec des enregistrements audio et des rediffusions disponibles sur le site des Relations Investisseurs de MindMed jusqu'à 90 jours après l'événement.
MindMed (NASDAQ: MNMD), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf Störungen der Gehirngesundheit konzentriert, hat seine Teilnahme an der bevorstehenden Leerink Global Healthcare Conference 2025 angekündigt. Das Management-Team des Unternehmens wird an einem informellen Gespräch und Einzelgesprächen während der Veranstaltung teilnehmen, die für den 11. März 2025 um 15:40 Uhr ET in Miami Beach, FL, geplant ist.
Interessierte Parteien können die Präsentation über einen Webcast abrufen, wobei Audioaufzeichnungen und Wiederholungen bis zu 90 Tage nach der Veranstaltung auf der Investoren-Relations-Website von MindMed verfügbar bleiben.
- None.
- None.
-
Leerink’s Global Healthcare Conference
- Format: Fireside Chat and 1x1 Meetings
- Date: March 11, 2025 at 3:40 PM ET
-
Location:
Miami Beach, FL - Webcast Link: Leerink’s Global Healthcare Conference 2025
Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304577180/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
When and where is MindMed (MNMD) presenting at Leerink's Global Healthcare Conference 2025?
How can investors access MindMed's (MNMD) presentation at the Leerink Conference?
What type of presentation format will MindMed (MNMD) deliver at Leerink's Conference?
How long will MindMed's (MNMD) Leerink Conference presentation be available for replay?
